Article info
PDFClinical science
Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)
- Correspondence to Dr Simon Dulz, Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; s.dulz{at}uke.de
Citation
Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)
Publication history
- Received February 22, 2022
- Accepted June 11, 2022
- First published June 30, 2022.
Online issue publication
October 18, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.